Skip to main content
. 2022 Feb 25;29(9):1730–1743. doi: 10.1038/s41418-022-00960-x

Fig. 3. OTUD6A is amplified and overexpressed in human PrCa, and positively correlated with c-Myc oncoprotein level.

Fig. 3

A OTUD6A was exclusively amplified in PrCa in TCGA. The genetic alternation of OTUD6A gene was analyzed among all cancer studies in TCGA database and classified by cancer study. These cancer studies with low frequency of OTUD6A alternation were not shown. B OTUD6A amplification preferentially occurred in metastatic PrCa in TCGA. C OTUD6A amplification led to increase in OTUD6A mRNA expression. N = 144, p = 0.046 in OTUD6A amplification group vs. diploid group. D OTUD6A gene alteration indicated worse prognosis of human PrCa. The overall survival of PrCa patients in TCGA with vs. without OTUD6A genetic alternation were compared (Median Months Survival: 39.32 vs. 120.00, p = 2.143 × 10−3, altered group: 40 cases; unaltered group: 2854 cases). E Representative immunohistochemistry (IHC) staining images of OTUD6A and c-Myc in normal prostate tissue and PrCa samples. F The expressions of OTUD6A were positively correlated with c-Myc staining scores in human PrCa samples. Chi-squared test, df = 9, χ2 = 24.709, p = 2.72 × 10−3. G Otud6a was highly expressed in sexual tissues/organs, including testis and prostate, in mice. Otud6a mRNA levels in different tissues/organs derived from C57 mice were analyzed by qPCR. The relevant raw data are provided in Supplementary Materials.